Mrunal Kurlekar

Ms. Mrunal Kurlekar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
PKPriyanka Kandhare
Priyanka Kandhare
MKMrunal Kurlekar
Mrunal Kurlekar
TDTanvi Tanvi Deshpande
Tanvi Tanvi Deshpande
APAtmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Background/Objectives: The integration of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical research and development is transforming the industry by improving efficiency and effectiveness across drug discovery, development, and healthcare delivery. This review explores the diverse applications of AI and ML, emphasizing their role in predictive modeling, drug repurposing, lead optimization, and clinical trials. Additionally, the review highlights AI’s contributions to regulatory compliance, pharmacovigilance, and personalized medicine while addressing ethical and regulatory considerations. Methods: A comprehensive literature review was conducted to assess the impact of AI and ML in various pharmaceutical domains. Research articles, case studies, and industry reports were analyzed to examine AI-driven advancements in predictive modeling, computational chemistry, clinical trials, drug safety, and supply chain management. Results: AI and ML have demonstrated significant advancements in pharmaceutical research, including improved target identification, accelerated drug discovery through generative models, and enhanced structure-based drug design via molecular docking and QSAR modeling. In clinical trials, AI streamlines patient recruitment, predicts trial outcomes, and enables real-time monitoring. AI-driven predictive maintenance, process optimization, and inventory management have enhanced efficiency in pharmaceutical manufacturing and supply chains. Furthermore, AI has revolutionized personalized medicine by enabling precise treatment strategies through genomic data analysis, biomarker discovery, and AI-driven diagnostics. Conclusions: AI and ML are reshaping pharmaceutical research, offering innovative solutions across drug discovery, regulatory compliance, and patient care. The integration of AI enhances treatment outcomes and operational efficiencies while raising ethical and regulatory challenges that require transparent, accountable applications. Future advancements in AI will rely on collaborative efforts to ensure its responsible implementation, ultimately driving the continued transformation of the pharmaceutical sector.

3 November 2026 in RSC Mechanochemistry
Verified
Journal Article
Open access
PTPooja Tiwary
Pooja Tiwary
KOKrishil Oswal
Krishil Oswal
SGShreya Gorantala
Shreya Gorantala
MKMrunal Kurlekar
Mrunal Kurlekar
RDRushikesh Dube
Rushikesh Dube
PGPardeep Gupta
Pardeep Gupta
This review highlights recent innovations in enzyme-responsive hydrogels, focusing on modular architectures, smart crosslinking strategies, advanced fabrication, translational barriers, and emerging applications in personalized medicine.